Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapy

Journal of Bone and Mineral Research

Volumn 23, Issue 8, 2008, Pages 1349-

  Bauer, Douglas C ^a   Vittinghof, Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; PLACEBO; RISEDRONIC ACID; TELOPEPTIDE;

BONE TURNOVER; INCIDENCE; LETTER; RISK REDUCTION; VERTEBRA FRACTURE;

BONE AND BONES; CLINICAL TRIALS AS TOPIC; COLLAGEN TYPE I; FRACTURES, BONE; HUMANS; PEPTIDES; RISK REDUCTION BEHAVIOR;

EID: 47849129538     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080320     Document Type: Letter

References (5)

1. Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD 2007 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: Review of statistical analysis. J Bone Miner Res 22:1656-1660.
2. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
3. Eisman JA, Lorenzo JA 2007 Challenges in science and academic-industry interactions. J Bone Miner Res 22:1654-1655.
4. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19:1250-1258.
5. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J 2004 Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351.